# Stem Cell Transplant for Hematologic Diseases

> **NCT00058825** · PHASE1,PHASE2 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 27 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** Campath 1H
- **DRUG:** Fludarabine
- **PROCEDURE:** Stem Cell Transplant
- **RADIATION:** Total Body Irradiation (TBI)
- **DRUG:** FK506 (Tacrolimus) or Cyclosporine

## Key facts

- **NCT ID:** NCT00058825
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Slow accrual due to practice changes meant study would take too long to finish
- **Last updated:** 2016-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058825, "Stem Cell Transplant for Hematologic Diseases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00058825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*